A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID/Post-Acute Sequalae of Covid (PASC)

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with long COVID/Post-Acute Sequelae of COVID (PASC). The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 6 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.

Start Date01 Sep 2025

Sponsor / Collaborator-

NCT06805656

/ Not yet recruitingPhase 2IIT

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Use of Antiretrovirals

A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patient to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.

Start Date01 Sep 2025

Sponsor / Collaborator

Universidade Federal De Sao Paulo

[+1]

NCT07080567

/ RecruitingPhase 2IIT

Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Start Date14 Jul 2025

Sponsor / Collaborator

Les Hôpitaux Universitaires de Genève

100 Clinical Results associated with Maraviroc

100 Translational Medicine associated with Maraviroc

100 Patents (Medical) associated with Maraviroc

1,827

Literatures (Medical) associated with Maraviroc

31 Dec 2025·ASN Neuro

Sex Affects Cognitive Outcomes in HIV-1 Tat Transgenic Mice: Role of CCR5

Article

Author: Boakye-Agyei, Ama ; Vo, Phu ; Simons, Chloe A. ; Nass, Sara R. ; Kim, Sarah ; Hahn, Yun K. ; Knapp, Pamela E. ; Hauser, Kurt F.

People living with HIV (PLWH) experience HIV-associated neurocognitive disorders (HAND), even though combination antiretroviral therapy (cART) suppresses HIV replication. HIV-1 transactivator of transcription (HIV-1 Tat) contributes to the development of HAND through neuroinflammatory and neurotoxic mechanisms. C-C chemokine 5 receptor (CCR5) is important in immune cell targeting and is a co-receptor for HIV viral entry into CD4+ cells. Notably, CCR5 has been implicated in cognition unrelated to HIV infection. Inhibition of CCR5 has been shown to improve learning and memory. To test whether CCR5 is involved in cognitive changes in HAND, we used a non-infectious, transgenic model in which HIV-1 Tat is inducibly expressed. Well-powered cohorts of male and female mice were placed on a diet containing doxycycline to induce Tat expression for 8-wks. Males showed Tat-mediated deficits in the Barnes maze test of spatial learning and memory; females showed no impairments. Deficits in the males were fully reversed by the CCR5 antagonist, maraviroc (MVC). Tat-mediated deficits were not found in novel object recognition or contextual fear conditioning in either sex. Based on earlier work, we hypothesized that MVC might increase brain-derived neurotrophic factor (BDNF), which is essential in maintaining synaptodendritic function. MVC did increase the mBDNF to proBDNF ratio in males, perhaps contributing to improved cognition.

01 Nov 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

C–C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology

Review

Author: Ghasemi, Kosar

The C-C motif chemokine ligand 5 (CCL5; also known as RANTES) and its primary G-protein-coupled receptor (GPCR), CCR5, establish complicated signaling pathways, affecting tumor progression through context-dependent immunomodulation and direct contacts with neoplastic cells. This review summarizes current structural and functional evidence linking CCL5's O-linked glycosylation, oligomerization, and glycosaminoglycan interactions to its affinity for CCR5, tissue retention, and gradient formation-molecular attributes that govern leukocyte recruitment, stromal remodeling, angiogenesis, and metastasis. It also discusses mechanistic data showing how CCL5/CCR5 signaling promotes protumorigenic processes, including the recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), polarization of tumor-associated macrophages (TAMs), epithelial-mesenchymal transition (EMT), stabilization of programmed cell death-ligand 1 (PD-L1), and therapeutic resistance. In particular, in immune-activating conditions, the recruitment of conventional type 1 dendritic cells (cDC1s), natural killer (NK) cells, and CD8⁺ T cells is augmented, hence fortifying anticancer immunity. Data from several tumors reveal both detrimental and beneficial effects, dependent on the tumor microenvironment (TME) and therapeutic context. Translational techniques employing CCR5 antagonists such as Maraviroc, GAG-binding modulators, glycoengineered CCL5 variants, delivery systems, and their integration with immune checkpoint inhibitors (ICIs) and targeted therapies are highlighted for their considerable therapeutic promise. Critical research priorities, encompassing single-cell phenotyping, CRISPR-mediated screening of chemokine pathways, and structural-functional mapping, are outlined to facilitate precise modulation of the CCL5/CCR5 axis in targeted cancer therapy. This review addresses structural biology and tumor immunology to identify the CCL5/CCR5 axis as a multifaceted yet promising biological target for innovative cancer therapeutics.

01 Oct 2025·BRAIN BEHAVIOR AND IMMUNITY

Prenatal alcohol exposure induces microglia to release exosomes with an elevated level of MIP-1α that participates in apoptotic process of stress-regulatory proopiomelanocortin neurons via glutamate excitotoxicity

Article

Author: Sarkar, Dipak K ; Tarale, Prashant ; Chaudhary, Shaista

Microglia are known to participate in ethanol-activated neuronal death of stress-regulatory proopiomelanocortin (POMC) neurons in the hypothalamus leading to hyper corticosterone response to stress and anxiety-like behaviors in a rat model of fetal alcohol spectrum disorder. We recently reported that ethanol-activated microglia release small membrane-bound vesicles called exosomes, which carry various neuroinflammatory molecules involved in POMC neuronal death. Here, we determined if macrophage inflammatory protein (MIP)-1α, a neuroinflammatory chemokine participates in ethanol-induced POMC neuronal death during the developmental period. We used an in vitro model, consisting of primary culture of hypothalamic microglia prepared from postnatal day 2 (PND2) rat and treated with or without 50 mM ethanol for 24 h, and an in vivo animal model in which hypothalamic microglia were obtained from PND6 rats fed daily with 2.5 mg/kg ethanol or control milk formula between PND2-6. We found that ethanol elevated MIP-1α level in microglial exosomes both in vitro and in vivo models. Ethanol-activated microglial exosomes when introduced into primary cultures of β-endorphin-producing POMC neurons, increased cellular levels of MIP-1α and chemokine receptor CCR5 related signaling molecules including glutamate transporter-1 and NMDA receptor subunit genes, calcium influx, inflammatory cytokines and apoptotic genes causing apoptotic death of POMC neurons. These effect of microglial exosomes on POMC neurons were suppressed by a CCR5 antagonist Maraviroc. Maraviroc administrated in postnatal PAE rats, reduces the ethanol-induced death of POMC neurons in developing hypothalamus and suppressed stress-related corticosterone hyperresponse and anxiety-like behaviors during adulthood. These findings indicate that alcohol exposure during the developmental period increases MIP-1α levels in microglial exosomes, which activate CCR5 signaling and cause apoptosis in POMC neurons, leading to hormonal and behavioral stress response abnormalities in animals.

News (Medical) associated with Maraviroc

10 Feb 2025

·www.globenewswire.com

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antiviral Agents, TNX-3900 with a Host-Directed Mechanism Tonix Plans to Develop the TNX-3900 Series of Molecules as Oral Antivirals Either as Monotherapy or in Combination with Other Antivirals The TNX-3900 Class of Antivirals Has a Novel Mechanism of Action Based on Inhibition of Certain Cathepsin Proteases which are Required for Cell Infection by Many Viruses like SARS-CoV-2 Sina Bavari, Ph.D., Tonix EVP of Infectious Disease R&D and Director of the Frederick, MD Research and Development Center (RDC) was a Scientific Founder of Healion Bio, Inc. Feb. 02, 2023 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2. “We are excited to develop Healion’s drug programs that include TNX-3900, which is a class of drugs with potential broad spectrum anti-viral activity, either as monotherapies or in combination with other antivirals”, said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Broad-spectrum antiviral agents have the potential to reduce viral load and allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Examples of other classes of host-directed antivirals that have been approved by the U.S. Food and Drug Administration (FDA) include alpha interferon like Pegasys® (peginterferon alfa-2a) for viral hepatitis, the CCR5 antagonist Selzentry® (maraviroc) for HIV, and the anti-IL-6 receptor antagonist monoclonal antibody Actemra® (tocilizumab) for COVID-19.” Sina Bavari, Ph.D., Executive Vice President for Infectious Disease Research at Tonix said, “I am pleased to be reunited with the infectious disease assets of Healion, since I was the scientific founder of Healion after I retired from my position as Chief of R&D at the United States Army Medical Research Institute of Infectious Disease (USAMRIID). While Healion made some progress developing these advanced technologies, Tonix’s state-of-the art facilities and depth of drug development expertise have the potential to advance the TNX-3900 class of drugs into clinical trials. On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.” TNX-3900 is the term for a series of molecules that inhibit essential cathepsins which are required by viruses such as coronaviruses and filoviruses to infect cells. Because of the unique antiviral mechanism of these compounds, the Company believes they can potentiate the activity of other antivirals with differing mechanisms. The Company believes this makes cathepsin inhibitors suitable for combination therapy. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the second quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second quarter of 2023. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, TNX-801, a next-generation vaccine to prevent COVID-19, TNX-1850, a platform to make fully human monoclonal antibodies to treat COVID-19, TNX-3600, and humanized anti-SARS-CoV-2 monoclonal antibodies, TNX-3800, recently licensed from Curia. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the second half of 2023. The content above comes from the network. if any infringement, please contact us to modify.

VaccineBreakthrough TherapyImmunotherapyOrphan Drug

16 May 2024

·www.biospace.com

Venatorx Pharmaceuticals Announces Changes to Executive Leadership

MALVERN, Pa.--(BUSINESS WIRE)-- Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team. Manos Perros, PhD, has been appointed to the Board of Directors as Executive Chairman. Dr. Perros is a distinguished pharmaceutical and biotech executive with an impressive track record that includes more than 25 years in life sciences research and development. He was previously Chief Executive Officer and co-founder of Entasis Therapeutics, where he successfully positioned the company as a leader in the antimicrobial space, resulting in its acquisition by Innoviva in 2022. While at Entasis, Dr. Perros oversaw the development of Xacduro, which recently earned U.S. Food and Drug Administration approval as the first targeted treatment for Acinetobacter baumannii pneumonia. Prior to founding Entasis, Dr. Perros held the positions of Vice President and Head of AstraZeneca’s Infection Research and Early Development organization and Site Head for AstraZeneca’s Boston R&D research center. Dr. Perros also served as Director of the Novartis Institute for Tropical Diseases in Singapore, and Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, where he led an R&D program that culminated in the approval of Selzentry, a first-in-class treatment for HIV. Dr. Perros’ appointment follows the resignation of Christopher J. Burns, Ph.D., who has stepped down as Chief Executive Officer and Director of Venatorx Pharmaceuticals. Additionally, Tomas J. Heyman has stepped down as Non-Executive Chairman of the Board. “On behalf of the entire Company, I would like to personally thank Chris for his dedication and tireless perseverance to lead Venatorx for over 14 years as an innovative pioneer in the fight against anti-microbial resistance. The Board of Directors sincerely appreciates his contributions along with the endless support and leadership that have guided the Company toward achieving its mission. I am delighted to join Venatorx Pharmaceuticals and to have an opportunity to help advance cefepime-taniborbactam through regulatory review and toward FDA approval to address the growing unmet need for novel treatments for patients suffering from multi-drug resistant gram-negative bacterial infections,” Dr. Perros said. “As recent Phase III data in The New England Journal of Medicine established, cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis, while having a similar safety pro meropenem. This therapy has enormous potential and may represent a significant improvement over the standard of care that could support global health efforts to combat antibiotic-resistant infections for patients around the world.” About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections. Venatorx is also developing an oral antibacterial, ceftibuten-ledaborbactam (formerly known as VNRX-7145), for the treatment of cUTI, including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options; this product is completing Phase 1 and will advance directly to a global Phase 3 cUTI clinical trial. For more information about Venatorx and its anti-infectives portfolio, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical development of Venatorx Pharmaceuticals’ product candidates.

Phase 3Executive ChangeDrug ApprovalAcquisitionClinical Result

15 Feb 2024

·www.prnewswire.com

HealthBioAI Announces the Acceptance by the Federal Drug Administration (FDA) to Proceed with a Randomized Clinical Trial for the Treatment of Long COVID/Post Acute Sequelae of COVID (PASC) with Selzentry® (maraviroc) in Combination with Lipitor (atorvastatin)

- New Company to support New Drug Application- HAYWARD, Calif., Feb. 15, 2024 /PRNewswire/ -- HealthBioAI, a recently launched precision immunology company advancing new science for neglected immune-mediated diseases, today announced that the company's clinical trial design to investigate the treatment of patients with Long COVID/Post-Acute Sequelae of COVID (PASC) with Selzentry (maraviroc) tablets and Lipitor (atorvastatin) tablets is accepted to proceed with a randomized clinical trial. The clinical trial will support a New Drug Application (NDA) filing through the 505(B)(2) pathway of the Federal Food, Drug, and Cosmetic Act (FDCA). The Clinical Trial is a 32-week randomized, 252 patient, double-blind, placebo-controlled, multicenter study that is evaluating the safety and efficacy of maraviroc and atorvastatin for the treatment of patients living with Long COVID/Post-Acute Sequelae of Covid (PASC). "We are excited to come out of extensive integration to launch our new enterprise, HealthBioAI. We have combined Machine Learning driven precision diagnostics of IncellDx, a diagnostics company, with our proprietary data analytics AI portal to fuel new drug discovery. This work has culminated in our first successful filing and acceptance from the FDA for our long COVID clinical trial," said Bruce Patterson, M.D., founder and CEO at HealthBioAI. "Some people who have been infected with the virus that causes COVID-19 can experience long-term effects from their infection, known as Long COVID or Post-COVID Conditions (PCC). Long COVID is a debilitating condition in which patients often go undiagnosed and without treatment. Symptoms of the disease can last weeks, months or even years and often impact work, daily household tasks, and even getting out of bed. HealthBioAI, is pleased about the potential therapeutic value of our combination regimen for treatment of Long COVID," said Stefan Glück, M.D, Ph.D.; senior vice president, Medical Affairs at HealthBioAI. "While the two existing therapies have been individually approved as stand-alone treatments in use for more than a decade for cholesterol and infectious diseases with well documented safety profiles, our research has found that when the therapies are combined, they may hold the key to suppressing the blood vessel inflammation believed to be at the root of Long COVID." The protocol of maraviroc and atorvastatin addresses the CCR5 pathway, reducing vascular inflammation with the potential to improve patient outcomes. A study was published earlier this year in a peer reviewed journal where Long COVID patients were given maraviroc (300 mg per oral twice a day) and pravastatin (10 mg per oral daily) showed improvements in both subjective symptoms and the objective measure of the biomarkers that characterize Long COVID. In 2021, a patent was awarded for the use of maraviroc to treat COVID-19 and Long COVID, which is now held by HealthBioAI. About Long Covid Long COVID is referred to by many names, including Post-COVID Conditions, long-haul COVID, post-acute COVID-19, long-term effects of COVID, and chronic COVID. The term post-acute sequelae of SARS CoV-2 infection (PASC) is also used to refer to a subset of Long COVID. Long COVID may not affect everyone the same way. People with Long COVID may experience health problems from different types and combinations of symptoms that may emerge, persist, resolve, and reemerge over different lengths of time. Long COVID is estimated to affect nearly 20 million people across the United States and more than 65 million worldwide. Long COVID is broadly defined as signs, symptoms, and conditions that continue or develop after acute COVID-19 infection. This definition of Long COVID was developed by the Department of Health and Human Services (HHS) in collaboration with CDC and other partners. About HealthBioAI HealthBioAI, a recently launched company has identified a common thread in chronic inflammatory diseases through the use of machine learning and AI-based precision diagnostics. HealthBioAI is initially focused on precision immune modulation of neglected diseases, including Long COVID, Chronic Fatigue Syndrome (ME-CFS) and Chronic Lyme Disease. The company aims to improve diagnosis, advance new science, and innovate new medicines for these historically minimally characterized diseases. For more information or investment inquiries, please contact us at . Media Contact: Julie Ferguson [email protected] [email protected] (312) 385-0098 Investor Relations: Chris Wheeler Chief Financial Officer [email protected] [email protected] (415) 595-4911 SOURCE HealthBioAI

Clinical StudyNDAEmergency Use Authorization

100 Deals associated with Maraviroc

External Link

KEGG	Wiki	ATC	Drug Bank
D06670	Maraviroc	J05AX09	DB04835

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	06 Aug 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fatty Liver	Phase 3	United Kingdom	ViiV Healthcare Ltd.	01 Mar 2017
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United Kingdom	ViiV Healthcare Ltd.	01 Mar 2017
AIDS Dementia Complex	Phase 3	United States	ViiV Healthcare Ltd.	01 Jun 2015
AIDS Dementia Complex	Phase 3	Puerto Rico	ViiV Healthcare Ltd.	01 Jun 2015
Cardiovascular Diseases	Phase 3	United States	Pfizer Inc.	01 Jan 2010
Inflammation	Phase 3	United States	Pfizer Inc.	01 Jan 2010
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	Pfizer Inc.	01 Jul 2007
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	ViiV Healthcare Ltd.	01 Jul 2007
COVID-19	Phase 2	Spain	ViiV Healthcare Ltd.	26 Jun 2020
AIDS-related Kaposi Sarcoma	Phase 2	United States	ViiV Healthcare Ltd.	09 Mar 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05932550 (Pubmed)	Phase 2	Depressive Disorder Add-on CCR5	10	Maraviroc 300 mg	psbcjerhvt(zlxapnsrre) = nyoeorzojl xmbhusiycr (eaomqexejg, 9.3)	Positive	06 Jun 2024
NCT02881762 (MAVERIC, CTgov)	Phase 4	HIV Infections \| Hepatitis C	10	Maraviroc (Maraviroc)	gdebrxykad(ftjjdyyytu) = edeoialhjf luiptlykyx (pspdrabpdw, 1012880) View more	-	01 May 2024
				Maraviroc (No Maraviroc)	gdebrxykad(ftjjdyyytu) = ftpgpzohoz luiptlykyx (pspdrabpdw, 1411027) View more
NCT04435522 (CTgov)	Phase 1	COVID-19	9	maraviroc	gcyebguhiv = lklhmdmwcr sducvhcxsf (eogxaibazr, rrbzwhcrda - mcurpchzgn) View more	-	29 Apr 2024
NCT02741323 (CTgov)	Phase 2	Kidney Diseases \| HIV Infections	97	maraviroc (Arm 1: Maraviroc (MVC))	chjrhbhaux(jzfkklalkd) = rnflmkfpgc udpzpbpsqj (oganrtdxvk, rgxcrjfskq - pmbdgbyaac) View more	-	21 Aug 2023
				Placebo (Arm 2: Placebo)	chjrhbhaux(jzfkklalkd) = qahjhabvcf udpzpbpsqj (oganrtdxvk, fkutosdagj - xeqqtyurzc) View more
NCT00948753 (CTgov)	Phase 1/2	Hematopoietic stem cell transplantation \| Graft vs Host Disease	38	Maraviroc 150 MG (Phase 1: 150mg Maraviroc)	aetcuznwaf = agnozgegxy uuyguuvzul (jtqkradqyb, zahczrofxm - sceqpsinmx) View more	-	17 May 2022
				Maraviroc 300 mg (Phase 1: 300mg Maraviroc)	aetcuznwaf = eejeognysj uuyguuvzul (jtqkradqyb, zhtjamgjlt - ulcbzxfsta) View more
NCT02519777 (CTgov)	Phase 4	Cognitive Dysfunction \| HIV Infections	191	Placebo for dolutegravir (DTG) (Arm A: Placebo MVC and Placebo DTG)	hxqgmernyn(uadlctpsau) = chzubkjble qeaebqjigw (cjffjothyp, qyzihviwft - wuzzerolnf) View more	-	02 Mar 2022
				Placebo for maraviroc (MVC)+Dolutegravir (DTG) (Arm B: DTG and Placebo MVC)	hxqgmernyn(uadlctpsau) = pqojtzxkgp qeaebqjigw (cjffjothyp, ghmgrwlicr - dfoufxjuen) View more
NCT03172026 (MAROS, CTgov)	Phase 2/3	Stroke	2	Rehabilitation therapy+Maraviroc 300 mg (Maraviroc + Augmented Rehabilitation)	tydmfqhygt(lwekvucxfr) = diczseukws vqpvuawier (pazvnvynay, lsiikswqlq - bfsodaqden) View more	-	03 Aug 2021
				Placebo 300 mg (Placebo + Augmented Rehabilitation)	tydmfqhygt(lwekvucxfr) = bctbpdgyxv vqpvuawier (pazvnvynay, lkirvogdav - yvalhinlnl) View more
NCT03274804 (PICCASSO, CTgov)	Phase 1	Spinocerebellar Degenerations \| Metastatic Microsatellite Stable Colorectal Carcinoma \| Metastatic Colorectal Carcinoma	20	Pembrolizumab+maraviroc	loixpfhdqc = kyyihbxayn pnhwahcwug (olugiulyyp, emfzomtitk - qffmmxyxsa) View more	-	22 Apr 2021
NCT01276236 (CTgov)	Phase 2	AIDS-related Kaposi Sarcoma	13	maraviroc	kneflwxadm = qyrjkkbpvw wcjosjeivu (axhvjcatcb, utbqpajfod - lkejythsew) View more	-	05 Mar 2021
NCT01785810 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Chronic Lymphocytic Leukemia \| Acute Lymphoblastic Leukemia ... View more	37	Maraviroc 300 mg	dblffffjqc = vcjanqsiwh uzohnzsteb (ynwdcbkyqx, ldphdktrjb - kmpwphgipc) View more	-	11 Jan 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Maraviroc

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation